Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition

Detalles Bibliográficos
Autores principales: de Silva, Madhawa, Itchins, Malinda, Pavlakis, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214900/
https://www.ncbi.nlm.nih.gov/pubmed/32411778
http://dx.doi.org/10.21037/atm.2020.01.87
_version_ 1783532071124205568
author de Silva, Madhawa
Itchins, Malinda
Pavlakis, Nick
author_facet de Silva, Madhawa
Itchins, Malinda
Pavlakis, Nick
author_sort de Silva, Madhawa
collection PubMed
description
format Online
Article
Text
id pubmed-7214900
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-72149002020-05-14 Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition de Silva, Madhawa Itchins, Malinda Pavlakis, Nick Ann Transl Med Editorial Commentary AME Publishing Company 2020-04 /pmc/articles/PMC7214900/ /pubmed/32411778 http://dx.doi.org/10.21037/atm.2020.01.87 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
de Silva, Madhawa
Itchins, Malinda
Pavlakis, Nick
Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
title Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
title_full Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
title_fullStr Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
title_full_unstemmed Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
title_short Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
title_sort breakthrough 5-year survival with pembrolizumab in keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214900/
https://www.ncbi.nlm.nih.gov/pubmed/32411778
http://dx.doi.org/10.21037/atm.2020.01.87
work_keys_str_mv AT desilvamadhawa breakthrough5yearsurvivalwithpembrolizumabinkeynote001studyhorizonshiftinginadvancednonsmallcelllungcancerwithimmunecheckpointinhibition
AT itchinsmalinda breakthrough5yearsurvivalwithpembrolizumabinkeynote001studyhorizonshiftinginadvancednonsmallcelllungcancerwithimmunecheckpointinhibition
AT pavlakisnick breakthrough5yearsurvivalwithpembrolizumabinkeynote001studyhorizonshiftinginadvancednonsmallcelllungcancerwithimmunecheckpointinhibition

Ejemplares similares